Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Jan;31(1):1–13. doi: 10.1111/j.1365-2125.1991.tb03851.x

Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

R J MacFadyen 1, K R Lees 1, J L Reid 1
PMCID: PMC1368406  PMID: 1849731

Abstract

1. There is a body of circumstantial and direct evidence supporting the existence and functional importance of a tissue based RAS at a variety of sites. 2. The relation between circulatory and tissue based systems is complex. The relative importance of the two in determining haemodynamic effects is unknown. 3. Despite the wide range of ACE inhibitors already available, it remains unclear whether there are genuine differences related to tissue specificity. 4. Pathological states such as chronic cardiac failure need to be explored with regard to the contribution of tissue based ACE activities in generating acute and chronic haemodynamic responses to ACE inhibitors. 5. The role of tissue vs plasma ACE activity may be clarified by study of the relation between drug concentration and haemodynamic effect, provided that the temporal dissociation is examined and linked to circulating and tissue based changes in ACE activity, angiotensin peptides and sympathetic hormones.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acampora G. A., Melendez J. A., Keefe D. L., Turnbull A. D., Bedford R. F. Intraoperative administration of the intravenous angiotensin-converting enzyme inhibitor, enalaprilat, in a patient with congestive heart failure. Anesth Analg. 1989 Dec;69(6):833–839. [PubMed] [Google Scholar]
  2. Ader R., Chatterjee K., Ports T., Brundage B., Hiramatsu B., Parmley W. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation. 1980 May;61(5):931–937. doi: 10.1161/01.cir.61.5.931. [DOI] [PubMed] [Google Scholar]
  3. Admiraal P. J., Derkx F. H., Danser A. H., Pieterman H., Schalekamp M. A. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension. 1990 Jan;15(1):44–55. doi: 10.1161/01.hyp.15.1.44. [DOI] [PubMed] [Google Scholar]
  4. Ajayi A. A., Hockings N., Reid J. L. The relationship between serum enalaprilat concentration and the hypotensive effect in man. Int J Clin Pharmacol Res. 1987;7(1):1–3. [PubMed] [Google Scholar]
  5. Alhenc-Gelas F., Weare J. A., Johnson R. L., Jr, Erdös E. G. Measurement of human converting enzyme level by direct radioimmunoassay. J Lab Clin Med. 1983 Jan;101(1):83–96. [PubMed] [Google Scholar]
  6. Alhenc-Gélas F., Soubrier F., Hubert C., Allegrini J., Corvol P. The peculiar characteristics of the amino acid sequence of angiotensin I-converting enzyme, as determined by cDNA cloning of the human endothelial enzyme. J Cardiovasc Pharmacol. 1989;14 (Suppl 4):S6–S9. [PubMed] [Google Scholar]
  7. Allen A. M., Chai S. Y., Clevers J., McKinley M. J., Paxinos G., Mendelsohn F. A. Localization and characterization of angiotensin II receptor binding and angiotensin converting enzyme in the human medulla oblongata. J Comp Neurol. 1988 Mar 8;269(2):249–264. doi: 10.1002/cne.902690209. [DOI] [PubMed] [Google Scholar]
  8. Anand I. S., Ferrari R., Kalra G. S., Wahi P. L., Poole-Wilson P. A., Harris P. C. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989 Aug;80(2):299–305. doi: 10.1161/01.cir.80.2.299. [DOI] [PubMed] [Google Scholar]
  9. Bayliss J., Norell M., Canepa-Anson R., Sutton G., Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987 Jan;57(1):17–22. doi: 10.1136/hrt.57.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Belz G. G., Kirch W., Kleinbloesem C. H. Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics. Clin Pharmacokinet. 1988 Nov;15(5):295–318. doi: 10.2165/00003088-198815050-00003. [DOI] [PubMed] [Google Scholar]
  11. Benjamin N., Cockcroft J. R., Collier J. G., Dollery C. T., Ritter J. M., Webb D. J. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 1989 May;412:543–555. doi: 10.1113/jphysiol.1989.sp017630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bernstein K. E., Martin B. M., Bernstein E. A., Linton J., Striker L., Striker G. The isolation of angiotensin-converting enzyme cDNA. J Biol Chem. 1988 Aug 15;263(23):11021–11024. [PubMed] [Google Scholar]
  13. Biollaz J., Schelling J. L., Jacot Des Combes B., Brunner D. B., Desponds G., Brunner H. R., Ulm E. H., Hichens M., Gomez H. J. Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol. 1982 Sep;14(3):363–368. doi: 10.1111/j.1365-2125.1982.tb01992.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Burnier M., Waeber B., Nussberger J., Brunner H. R. Pharmacokinetics of angiotensin converting enzyme inhibitors. Br J Clin Pharmacol. 1989;28 (Suppl 2):133S–140S. doi: 10.1111/j.1365-2125.1989.tb03588.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Bühler F. R. Antihypertensive treatment according to age, plasma renin and race. Drugs. 1988 May;35(5):495–503. doi: 10.2165/00003495-198835050-00001. [DOI] [PubMed] [Google Scholar]
  16. Campbell D. J. Circulating and tissue angiotensin systems. J Clin Invest. 1987 Jan;79(1):1–6. doi: 10.1172/JCI112768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Campbell D. J., Ziogas J., Kladis A. Metabolism of tetradecapeptide, angiotensinogen and angiotensin I and II by isolated perfused rat hindlimbs. Clin Exp Pharmacol Physiol. 1990 May;17(5):335–350. doi: 10.1111/j.1440-1681.1990.tb01330.x. [DOI] [PubMed] [Google Scholar]
  18. Case D. B., Wallace J. M., Keim H. J., Weber M. A., Sealey J. E., Laragh J. H. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med. 1977 Mar 24;296(12):641–646. doi: 10.1056/NEJM197703242961201. [DOI] [PubMed] [Google Scholar]
  19. Catravas J. D., White R. E. Kinetics of pulmonary angiotensin-converting enzyme and 5'-nucleotidase in vivo. J Appl Physiol Respir Environ Exerc Physiol. 1984 Oct;57(4):1173–1181. doi: 10.1152/jappl.1984.57.4.1173. [DOI] [PubMed] [Google Scholar]
  20. Chai S. Y., McKenzie J. S., McKinley M. J., Mendelsohn F. A. Angiotensin converting enzyme in the human basal forebrain and midbrain visualized by in vitro autoradiography. J Comp Neurol. 1990 Jan 8;291(2):179–194. doi: 10.1002/cne.902910203. [DOI] [PubMed] [Google Scholar]
  21. Chatterjee K., Opie L. H. Angiotensin inhibitors and other vasodilators with special reference to congestive heart failure. Cardiovasc Drugs Ther. 1987;1(1):1–8. doi: 10.1007/BF02125827. [DOI] [PubMed] [Google Scholar]
  22. Chen X., Pitt B. R., Moalli R., Gillis C. N. Correlation between lung and plasma angiotensin converting enzyme and the hypotensive effect of captopril in conscious rabbits. J Pharmacol Exp Ther. 1984 Jun;229(3):649–653. [PubMed] [Google Scholar]
  23. Chevillard C., Brown N. L., Jouquey S., Mathieu M. N., Laliberté F., Hamon G. Cardiovascular actions and tissue-converting enzyme inhibitory effects of chronic enalapril and trandolapril treatment of spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1989 Aug;14(2):297–301. doi: 10.1097/00005344-198908000-00017. [DOI] [PubMed] [Google Scholar]
  24. Chevillard C., Saavedra J. M. Distribution of angiotensin-converting enzyme activity in specific areas of the rat brain stem. J Neurochem. 1982 Jan;38(1):281–284. doi: 10.1111/j.1471-4159.1982.tb10883.x. [DOI] [PubMed] [Google Scholar]
  25. Cleland J. G., Dargie H. J., Ball S. G., Gillen G., Hodsman G. P., Morton J. J., East B. W., Robertson I., Ford I., Robertson J. I. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J. 1985 Sep;54(3):305–312. doi: 10.1136/hrt.54.3.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Cleland J. G., Dargie H. J., McAlpine H., Ball S. G., Morton J. J., Robertson J. I., Ford I. Severe hypotension after first dose of enalapril in heart failure. Br Med J (Clin Res Ed) 1985 Nov 9;291(6505):1309–1312. doi: 10.1136/bmj.291.6505.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Cleland J. G., Dargie H. J., Robertson I., Robertson J. I., East B. W. Total body electrolyte composition in patients with heart failure: a comparison with normal subjects and patients with untreated hypertension. Br Heart J. 1987 Sep;58(3):230–238. doi: 10.1136/hrt.58.3.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Cleland J., Semple P., Hodsman P., Ball S., Ford I., Dargie H. Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure. Am J Med. 1984 Nov;77(5):880–886. doi: 10.1016/0002-9343(84)90530-8. [DOI] [PubMed] [Google Scholar]
  29. Cody R. J. Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review. Drugs. 1984 Aug;28(2):144–169. doi: 10.2165/00003495-198428020-00004. [DOI] [PubMed] [Google Scholar]
  30. Cohen M. L., Kurz K. D. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther. 1982 Jan;220(1):63–69. [PubMed] [Google Scholar]
  31. Corvol P., Clauser E., Waeber B. Circulating and tissular renin-angiotensin systems. J Cardiovasc Pharmacol. 1989;14 (Suppl 4):v–vi. [PubMed] [Google Scholar]
  32. De Marco T., Daly P. A., Liu M., Kayser S., Parmley W. W., Chatterjee K. Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure. J Am Coll Cardiol. 1987 May;9(5):1131–1138. doi: 10.1016/s0735-1097(87)80318-2. [DOI] [PubMed] [Google Scholar]
  33. De Silva P. E., Husain A., Smeby R. R., Khairallah P. A. Measurement of immunoreactive angiotensin peptides in rat tissues: some pitfalls in angiotensin II analysis. Anal Biochem. 1988 Oct;174(1):80–87. doi: 10.1016/0003-2697(88)90521-0. [DOI] [PubMed] [Google Scholar]
  34. Donnelly R., Meredith P. A., Elliott H. L. Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists. Clin Pharmacokinet. 1989 Oct;17(4):264–274. doi: 10.2165/00003088-198917040-00004. [DOI] [PubMed] [Google Scholar]
  35. Dzau V. J. Cardiac renin-angiotensin system. Molecular and functional aspects. Am J Med. 1988 Mar 11;84(3A):22–27. doi: 10.1016/0002-9343(88)90201-x. [DOI] [PubMed] [Google Scholar]
  36. Dzau V. J. Short- and long-term determinants of cardiovascular function and therapy: contributions of circulating and tissue renin-angiotensin systems. J Cardiovasc Pharmacol. 1989;14 (Suppl 4):S1–S5. [PubMed] [Google Scholar]
  37. Dzau V. J. Significance of the vascular renin-angiotensin pathway. Hypertension. 1986 Jul;8(7):553–559. doi: 10.1161/01.hyp.8.7.553. [DOI] [PubMed] [Google Scholar]
  38. Eglème C., Cressier F., Wood J. M. Local formation of angiotensin II in the rat aorta: effect of endothelium. Br J Pharmacol. 1990 Jun;100(2):237–240. doi: 10.1111/j.1476-5381.1990.tb15788.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ehlers M. R., Riordan J. F. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry. 1989 Jun 27;28(13):5311–5318. doi: 10.1021/bi00439a001. [DOI] [PubMed] [Google Scholar]
  40. El-Dorry H. A., Bull H. G., Iwata K., Thornberry N. A., Cordes E. H., Soffer R. L. Molecular and catalytic properties of rabbit testicular dipeptidyl carboxypeptidase. J Biol Chem. 1982 Dec 10;257(23):14128–14133. [PubMed] [Google Scholar]
  41. Erdös E. G. Angiotensin I converting enzyme. Circ Res. 1975 Feb;36(2):247–255. doi: 10.1161/01.res.36.2.247. [DOI] [PubMed] [Google Scholar]
  42. Ertl G. Angiotensin converting enzyme inhibitors and ischaemic heart disease. Eur Heart J. 1988 Jul;9(7):716–727. doi: 10.1093/eurheartj/9.7.716. [DOI] [PubMed] [Google Scholar]
  43. Ertl G., Kloner R. A., Alexander R. W., Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation. 1982 Jan;65(1):40–48. doi: 10.1161/01.cir.65.1.40. [DOI] [PubMed] [Google Scholar]
  44. Fabris B., Jackson B., Cubela R., Mendelsohn F. A., Johnston C. I. Angiotensin converting enzyme in the rat heart: studies of its inhibition in vitro and ex vivo. Clin Exp Pharmacol Physiol. 1989 Apr;16(4):309–313. doi: 10.1111/j.1440-1681.1989.tb01563.x. [DOI] [PubMed] [Google Scholar]
  45. Ferner R. E., Wilson D., Paterson J. R., Wilkinson R., Rawlins M. D. The effects of intradermal bradykinin are potentiated by angiotensin converting enzyme inhibitors in hypertensive patients. Br J Clin Pharmacol. 1989 Mar;27(3):337–342. doi: 10.1111/j.1365-2125.1989.tb05374.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Flynn K., Coughlan M. G., Phelan D. M., Luke D., Neligan M., Wood A. E. Intravenous captopril in acute heart failure. Lancet. 1988 Jan 23;1(8578):173–174. doi: 10.1016/s0140-6736(88)92737-7. [DOI] [PubMed] [Google Scholar]
  47. Foresti V., Pepe R., Parisio E., De Filippi G., Scolari N., Frigerio C. Angiotensin-converting enzyme as a possible marker for lung toxicity in amiodarone-treated patients. Int J Clin Pharmacol Res. 1989;9(4):261–267. [PubMed] [Google Scholar]
  48. Francis R. J., Brown A. N., Kler L., Fasanella d'Amore T., Nussberger J., Waeber B., Brunner H. R. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol. 1987 Jan;9(1):32–38. [PubMed] [Google Scholar]
  49. Friedland J., Setton C., Silverstein E. Induction of angiotensin converting enzyme in human monocytes in culture. Biochem Biophys Res Commun. 1978 Aug 14;83(3):843–849. doi: 10.1016/0006-291x(78)91471-7. [DOI] [PubMed] [Google Scholar]
  50. Fyhrquist F., Grönhagen-Riska C., Forslund T., Tikkanen I. Induction of angiotensin I-converting enzyme in rat lung with captopril: the effect of adrenalectomy. Am J Cardiol. 1982 Apr 21;49(6):1508–1510. doi: 10.1016/0002-9149(82)90370-8. [DOI] [PubMed] [Google Scholar]
  51. Fyhrquist F., Tikkanen I., Grönhagen-Riska C., Hortling L., Hichens M. Inhibitor binding assay for angiotensin-converting enzyme. Clin Chem. 1984 May;30(5):696–700. [PubMed] [Google Scholar]
  52. Ganong W. F. The brain renin-angiotensin system. Annu Rev Physiol. 1984;46:17–31. doi: 10.1146/annurev.ph.46.030184.000313. [DOI] [PubMed] [Google Scholar]
  53. Ganten D., Hermann K., Unger T., Lang R. E. The tissue renin-angiotensin systems: focus on brain angiotensin, adrenal gland and arterial wall. Clin Exp Hypertens A. 1983;5(7-8):1099–1118. doi: 10.3109/10641968309048844. [DOI] [PubMed] [Google Scholar]
  54. Gasic S., Dudczak R., Korn A., Kleinbloesem C. ACE inhibition with cilazapril improves myocardial perfusion to the ischemic regions during exercise: a pilot study. J Cardiovasc Pharmacol. 1990 Feb;15(2):227–232. doi: 10.1097/00005344-199002000-00008. [DOI] [PubMed] [Google Scholar]
  55. Gheorghiade M., Hall V., Lakier J. B., Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol. 1989 Jan;13(1):134–142. doi: 10.1016/0735-1097(89)90561-5. [DOI] [PubMed] [Google Scholar]
  56. Gibbs J. S., Cunningham D., Shapiro L. M., Park A., Poole-Wilson P. A., Fox K. M. Diurnal variation of pulmonary artery pressure in chronic heart failure. Br Heart J. 1989 Jul;62(1):30–35. doi: 10.1136/hrt.62.1.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Giles T. D., Katz R., Sullivan J. M., Wolfson P., Haugland M., Kirlin P., Powers E., Rich S., Hackshaw B., Chiaramida A. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol. 1989 May;13(6):1240–1247. doi: 10.1016/0735-1097(89)90294-5. [DOI] [PubMed] [Google Scholar]
  58. Herrlin B., Sylvén C., Nyquist O., Edhag O. Short term haemodynamic effects of converting enzyme inhibition before and after eating in patients with moderate heart failure caused by dilated cardiomyopathy: a double blind study. Br Heart J. 1990 Jan;63(1):26–31. doi: 10.1136/hrt.63.1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Hinman L. M., Stevens C., Matthay R. A., Bernard J., Gee L. Angiotensin convertase activities in human alveolar macrophages: effects of cigarette smoking and sarcoidosis. Science. 1979 Jul 13;205(4402):202–203. doi: 10.1126/science.221980. [DOI] [PubMed] [Google Scholar]
  60. Hodsman G. P., Isles C. G., Murray G. D., Usherwood T. P., Webb D. J., Robertson J. I. Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J (Clin Res Ed) 1983 Mar 12;286(6368):832–834. doi: 10.1136/bmj.286.6368.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Holford N. H., Sheiner L. B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981 Nov-Dec;6(6):429–453. doi: 10.2165/00003088-198106060-00002. [DOI] [PubMed] [Google Scholar]
  62. Hornung R. S., Hillis W. S. The acute haemodynamic effects of intravenous enalaprilic acid (MK422) in patients with left ventricular dysfunction. Br J Clin Pharmacol. 1987 Jan;23(1):29–33. doi: 10.1111/j.1365-2125.1987.tb03005.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Ibarra-Rubio M. E., Pena J. C., Pedraza-Chaverri J. Kinetic and inhibitory characteristics of serum angiotensin-converting enzyme from nine mammalian species. Comp Biochem Physiol B. 1989;92(2):399–403. doi: 10.1016/0305-0491(89)90300-3. [DOI] [PubMed] [Google Scholar]
  64. Ideishi M., Sasaguri M., Ikeda M., Arakawa K. Substrate-dependent angiotensin II formation in the peripheral circulation. Life Sci. 1990;46(5):335–341. doi: 10.1016/0024-3205(90)90012-g. [DOI] [PubMed] [Google Scholar]
  65. Ikeda T., Nakayama D., Gomi T., Sakurai J., Yamazaki T., Yuhara M. Captopril, an angiotensin I-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases. Nephron. 1989;52(1):72–75. doi: 10.1159/000185584. [DOI] [PubMed] [Google Scholar]
  66. Iwata K., Lai C. Y., El-Dorry H. A., Soffer R. L. The NH2- and COOH-terminal sequences of the angiotensin-converting enzyme isozymes from rabbit lung and testis. Biochem Biophys Res Commun. 1982 Aug;107(3):1097–1103. doi: 10.1016/0006-291x(82)90634-9. [DOI] [PubMed] [Google Scholar]
  67. Jackson B., Cubela R. B., Johnston C. I. Inhibition of tissue angiotensin converting enzyme by perindopril: in vivo assessment in the rat using radioinhibitor binding displacement. J Pharmacol Exp Ther. 1988 Jun;245(3):950–955. [PubMed] [Google Scholar]
  68. Jackson B., Cubela R. B., Sakaguchi K., Johnston C. I. Characterization of angiotensin converting enzyme (ACE) in the testis and assessment of the in vivo effects of the ACE inhibitor perindopril. Endocrinology. 1988 Jul;123(1):50–55. doi: 10.1210/endo-123-1-50. [DOI] [PubMed] [Google Scholar]
  69. Jackson B., Cubela R., Johnston C. I. Angiotensin-converting enzyme (ACE) measurement in human serum using radioinhibitor ligand binding. Aust J Exp Biol Med Sci. 1986 Apr;64(Pt 2):149–155. doi: 10.1038/icb.1986.16. [DOI] [PubMed] [Google Scholar]
  70. Jackson B., Cubela R., Johnston C. I. Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension. J Hypertens. 1984 Aug;2(4):371–377. [PubMed] [Google Scholar]
  71. Jacobsen J., Poulsen K., Hunding A. Alternative routes for angiotensin-I conversion: kinetics of the renin-angiotensin system in mouse plasma. Eur J Clin Invest. 1988 Apr;18(2):178–183. doi: 10.1111/j.1365-2362.1988.tb02410.x. [DOI] [PubMed] [Google Scholar]
  72. Jederlinic P., Hill N. S., Ou L. C., Fanburg B. L. Lung angiotensin converting enzyme activity in rats with differing susceptibilities to chronic hypoxia. Thorax. 1988 Sep;43(9):703–707. doi: 10.1136/thx.43.9.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Johnson H., Drummer O. H. Hydrolysis of angiotensin I by peptidases in homogenates of rat lung and aorta. Biochem Pharmacol. 1988 Mar 15;37(6):1131–1136. doi: 10.1016/0006-2952(88)90521-7. [DOI] [PubMed] [Google Scholar]
  74. Johnston C. I., Cubela R., Jackson B. Relative inhibitory potency and plasma drug levels of angiotensin converting enzyme inhibitors in the rat. Clin Exp Pharmacol Physiol. 1988 Feb;15(2):123–129. doi: 10.1111/j.1440-1681.1988.tb01053.x. [DOI] [PubMed] [Google Scholar]
  75. Johnston C. I., Cubela R., Sakaguchi K., Jackson B. Angiotensin converting enzyme inhibition in plasma and tissues. Clin Exp Hypertens A. 1987;9(2-3):307–321. doi: 10.3109/10641968709164190. [DOI] [PubMed] [Google Scholar]
  76. Johnston C. I., Fabris B., Yamada H., Mendelsohn F. A., Cubela R., Sivell D., Jackson B. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens Suppl. 1989 Sep;7(5):S11–S16. [PubMed] [Google Scholar]
  77. Johnston C. I., Mendelsohn F. A., Cubela R. B., Jackson B., Kohzuki M., Fabris B. Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors. J Hypertens Suppl. 1988 Dec;6(3):S17–S22. [PubMed] [Google Scholar]
  78. KOCH-WESER J. NATURE OF THE INOTROPIC ACTION OF ANGIOTENSIN ON VENTRICULAR MYOCARDIUM. Circ Res. 1965 Mar;16:230–237. doi: 10.1161/01.res.16.3.230. [DOI] [PubMed] [Google Scholar]
  79. Kamei K., Shiraki Y., Koga T., Sakai K. Contribution of the tissue angiotensin converting enzyme to the antihypertensive effect of altiopril calcium (MC-838) in spontaneously hypertensive rats. J Pharm Pharmacol. 1989 Apr;41(4):279–280. doi: 10.1111/j.2042-7158.1989.tb06454.x. [DOI] [PubMed] [Google Scholar]
  80. Keane W. F., Anderson S., Aurell M., de Zeeuw D., Narins R. G., Povar G. Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. Ann Intern Med. 1989 Sep 15;111(6):503–516. doi: 10.7326/0003-4819-111-6-503. [DOI] [PubMed] [Google Scholar]
  81. Kelley J. Lavage angiotensin-converting enzyme as a marker of lung injury. Am Rev Respir Dis. 1988 Mar;137(3):531–534. doi: 10.1164/ajrccm/137.3.531. [DOI] [PubMed] [Google Scholar]
  82. Kelman A. W., Reid J. L., Millar J. A. Concentration effect modelling with converting enzyme inhibitors in man. Br J Clin Pharmacol. 1983 Apr;15(4):506–507. doi: 10.1111/j.1365-2125.1983.tb01542.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Kiowski W., van Brummelen P., Hulthén L., Amann F. W., Bühler F. R. Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation. Clin Pharmacol Ther. 1982 Jun;31(6):677–684. doi: 10.1038/clpt.1982.95. [DOI] [PubMed] [Google Scholar]
  84. Kirch W., Stroemer K., Hoogkamer J. F., Kleinbloesem C. H. The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril. Br J Clin Pharmacol. 1989;27 (Suppl 2):297S–301S. doi: 10.1111/j.1365-2125.1989.tb03495.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Klahr S. The kidney in hypertension--villain and victim. N Engl J Med. 1989 Mar 16;320(11):731–733. doi: 10.1056/NEJM198903163201110. [DOI] [PubMed] [Google Scholar]
  86. Kramer B., Topic N., Massie B. Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure. Br J Clin Pharmacol. 1982;14 (Suppl 2):143S–151S. doi: 10.1111/j.1365-2125.1982.tb02071.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Kubo S. H., Clark M., Laragh J. H., Borer J. S., Cody R. J. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol. 1987 Dec 1;60(16):1322–1328. doi: 10.1016/0002-9149(87)90615-1. [DOI] [PubMed] [Google Scholar]
  88. Kubo S. H., Cody R. J. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. Clin Pharmacokinet. 1985 Sep-Oct;10(5):377–391. doi: 10.2165/00003088-198510050-00001. [DOI] [PubMed] [Google Scholar]
  89. Kubo S. H., Cody R. J., Laragh J. H., Prida X. E., Atlas S. A., Yuan Z., Sealey J. E. Immediate converting-enzyme inhibition with intravenous enalapril in chronic congestive heart failure. Am J Cardiol. 1985 Jan 1;55(1):122–126. doi: 10.1016/0002-9149(85)90312-1. [DOI] [PubMed] [Google Scholar]
  90. LaBarre T. R., O'Connell J. B., Gunnar R. M. Captopril therapy for severe CHF: hypotensive response in presence of markedly elevated PRA. Am Heart J. 1982 Feb;103(2):308–309. doi: 10.1016/0002-8703(82)90513-0. [DOI] [PubMed] [Google Scholar]
  91. Lantz P., Enghoff E., Hedlund A., Hägg A. Hemodynamic results of perorally administered converting enzyme inhibitors in congestive heart failure. Scand J Urol Nephrol Suppl. 1984;79:129–132. [PubMed] [Google Scholar]
  92. Laragh J. H. Nephron heterogeneity: clue to the pathogenesis of essential hypertension and effectiveness of angiotensin-converting enzyme inhibitor treatment. Am J Med. 1989 Dec 26;87(6B):2S–14S. doi: 10.1016/0002-9343(89)90084-3. [DOI] [PubMed] [Google Scholar]
  93. Lees K. R., Kelman A. W., Reid J. L., Whiting B. Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding. J Pharmacokinet Biopharm. 1989 Oct;17(5):529–550. doi: 10.1007/BF01071348. [DOI] [PubMed] [Google Scholar]
  94. Lindpaintner K., Wilhelm M. J., Jin M., Unger T., Lang R. E., Schoelkens B. A., Ganten D. Tissue renin-angiotensin systems: focus on the heart. J Hypertens Suppl. 1987 Jul;5(2):S33–S38. doi: 10.1097/00004872-198707002-00007. [DOI] [PubMed] [Google Scholar]
  95. Linehan J. H., Bronikowski T. A., Rickaby D. A., Dawson C. A. Hydrolysis of a synthetic angiotensin-converting enzyme substrate in dog lungs. Am J Physiol. 1989 Dec;257(6 Pt 2):H2006–H2016. doi: 10.1152/ajpheart.1989.257.6.H2006. [DOI] [PubMed] [Google Scholar]
  96. Lipkin D. P., Poole-Wilson P. A. Treatment of chronic heart failure: a review of recent drug trials. Br Med J (Clin Res Ed) 1985 Oct 12;291(6501):993–996. doi: 10.1136/bmj.291.6501.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Marchetti J., Roseau S., Alhenc-Gelas F. Angiotensin I converting enzyme and kinin-hydrolyzing enzymes along the rabbit nephron. Kidney Int. 1987 Mar;31(3):744–751. doi: 10.1038/ki.1987.61. [DOI] [PubMed] [Google Scholar]
  98. Marre M., Leblanc H., Suarez L., Guyenne T. T., Ménard J., Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J (Clin Res Ed) 1987 Jun 6;294(6585):1448–1452. doi: 10.1136/bmj.294.6585.1448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Martin M. T., Holmquist B., Riordan J. F. An angiotensin converting enzyme inhibitor is a tight-binding slow substrate of carboxypeptidase A. J Inorg Biochem. 1989 May;36(1):39–50. doi: 10.1016/0162-0134(89)80011-x. [DOI] [PubMed] [Google Scholar]
  100. Massie B. M., Kramer B. L., Topic N. Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation. 1984 Jun;69(6):1135–1141. doi: 10.1161/01.cir.69.6.1135. [DOI] [PubMed] [Google Scholar]
  101. McMurray J., Lang C. C., Maclean D. D., McDevitt D. G., Struthers A. D. A survey of current use of angiotensin-converting-enzyme inhibitors by Scottish physicians in the treatment of chronic cardiac failure. Scott Med J. 1989 Apr;34(2):425–427. doi: 10.1177/003693308903400204. [DOI] [PubMed] [Google Scholar]
  102. Mebazaa A., Chevalier B., Mercadier J. J., Echter E., Rappaport L., Swynghedauw B. A review of the renin-angiotensin system in the normal heart. J Cardiovasc Pharmacol. 1989;14 (Suppl 4):S16–S20. [PubMed] [Google Scholar]
  103. Meldrum M. J., Westfall T. C. Angiotensin facilitation of 3H-norepinephrine release in central tissue of spontaneously hypertensive rats but not in Wistar-Kyoto rats: effects of sodium depletion. J Cardiovasc Pharmacol. 1986 May-Jun;8(3):582–587. [PubMed] [Google Scholar]
  104. Metzger R., Wagner D., Takahashi S., Suzuki F., Lindpaintner K., Ganten D. Tissue renin-angiotensin systems aspects of molecular biology and pharmacology. Clin Exp Hypertens A. 1988;10(6):1227–1238. doi: 10.1080/07300077.1988.11878913. [DOI] [PubMed] [Google Scholar]
  105. Michel J. B., Lattion A. L., Salzmann J. L., Cerol M. L., Philippe M., Camilleri J. P., Corvol P. Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction. Circ Res. 1988 Apr;62(4):641–650. doi: 10.1161/01.res.62.4.641. [DOI] [PubMed] [Google Scholar]
  106. Misumi J., Gardes J., Gonzalez M. F., Corvol P., Menard J. Angiotensinogen's role in ANG formation, renin release, and renal hemodynamics in isolated perfused kidney. Am J Physiol. 1989 Apr;256(4 Pt 2):F719–F727. doi: 10.1152/ajprenal.1989.256.4.F719. [DOI] [PubMed] [Google Scholar]
  107. Mizuno K., Nakamaru M., Higashimori K., Inagami T. Local generation and release of angiotensin II in peripheral vascular tissue. Hypertension. 1988 Mar;11(3):223–229. doi: 10.1161/01.hyp.11.3.223. [DOI] [PubMed] [Google Scholar]
  108. Moalli R., Howell R. E., Gillis C. N. Kinetics of captopril- and enalapril-induced inhibition of pulmonary angiotensin converting enzyme in vivo. J Pharmacol Exp Ther. 1985 Aug;234(2):372–377. [PubMed] [Google Scholar]
  109. Mooser V., Nussberger J., Juillerat L., Burnier M., Waeber B., Bidiville J., Pauly N., Brunner H. R. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol. 1990 Feb;15(2):276–282. doi: 10.1097/00005344-199002000-00015. [DOI] [PubMed] [Google Scholar]
  110. Morin J. P., Moulin B., Borghi H., Grise P., Fillastre J. P. Comparative regional distribution of angiotensin-I-converting enzyme in the rat, rabbit, dog, monkey and human kidneys. Ren Physiol Biochem. 1989 Mar-Apr;12(2):96–103. doi: 10.1159/000173183. [DOI] [PubMed] [Google Scholar]
  111. Mounier F., Hinglais N., Sich M., Gros F., Lacoste M., Deris Y., Alhenc-Gelas F., Gubler M. C. Ontogenesis of angiotensin-I converting enzyme in human kidney. Kidney Int. 1987 Nov;32(5):684–690. doi: 10.1038/ki.1987.261. [DOI] [PubMed] [Google Scholar]
  112. Mujais S. K., Fouad F. M., Textor S. C., Tarazi R. C., Bravo E. L., Hart N., Gifford R. W., Jr Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure. Br Heart J. 1984 Jul;52(1):63–71. doi: 10.1136/hrt.52.1.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Navar L. G., Rosivall L. Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics. Kidney Int. 1984 Jun;25(6):857–868. doi: 10.1038/ki.1984.102. [DOI] [PubMed] [Google Scholar]
  114. Neilly J. B., Clark C. J., Tweddel A., Rae A. P., Hughes D. M., Hutton I., Morton J. J., Stevenson R. D. Transpulmonary angiotensin II formation in patients with chronic stable cor pulmonale. Am Rev Respir Dis. 1987 Apr;135(4):891–895. doi: 10.1164/arrd.1987.135.4.891. [DOI] [PubMed] [Google Scholar]
  115. Ng K. K., Vane J. R. Fate of angiotensin I in the circulation. Nature. 1968 Apr 13;218(5137):144–150. doi: 10.1038/218144a0. [DOI] [PubMed] [Google Scholar]
  116. Nussberger J., Juillerat L., Perret F., Waeber B., Bellet M., Brunner J., Ménard J. Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans. Am Heart J. 1989 Mar;117(3):717–722. doi: 10.1016/0002-8703(89)90759-x. [DOI] [PubMed] [Google Scholar]
  117. Okamura T., Miyazaki M., Inagami T., Toda N. Vascular renin-angiotensin system in two-kidney, one clip hypertensive rats. Hypertension. 1986 Jul;8(7):560–565. doi: 10.1161/01.hyp.8.7.560. [DOI] [PubMed] [Google Scholar]
  118. Okamura T., Okunishi H., Ayajiki K., Toda N. Conversion of angiotensin I to angiotensin II in dog isolated renal artery: role of two different angiotensin II-generating enzymes. J Cardiovasc Pharmacol. 1990 Mar;15(3):353–359. doi: 10.1097/00005344-199003000-00002. [DOI] [PubMed] [Google Scholar]
  119. Oliver R. M., Peacock A. J., Fleming J. S., Waller D. G. Renal and pulmonary effects of angiotensin converting enzyme inhibition in chronic hypoxic lung disease. Thorax. 1989 Jun;44(6):513–515. doi: 10.1136/thx.44.6.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Packer M., Gottlieb S. S., Blum M. A. Immediate and long-term pathophysiologic mechanisms underlying the genesis of sudden cardiac death in patients with congestive heart failure. Am J Med. 1987 Mar 20;82(3A):4–10. doi: 10.1016/0002-9343(87)90126-4. [DOI] [PubMed] [Google Scholar]
  121. Packer M., Gottlieb S. S., Kessler P. D. Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. Basis of a new physiologic approach to control of arrhythmia. Am J Med. 1986 Apr 25;80(4A):23–29. doi: 10.1016/0002-9343(86)90337-2. [DOI] [PubMed] [Google Scholar]
  122. Packer M., Kessler P. D., Gottlieb S. S. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgrad Med J. 1986;62 (Suppl 1):179–182. [PubMed] [Google Scholar]
  123. Packer M., Medina N., Yushak M. Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. Circulation. 1985 Apr;71(4):761–766. doi: 10.1161/01.cir.71.4.761. [DOI] [PubMed] [Google Scholar]
  124. Packer M., Medina N., Yushak M., Lee W. H. Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients. Br Heart J. 1985 Sep;54(3):298–304. doi: 10.1136/hrt.54.3.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Packer M., Medina N., Yushak M., Meller J. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. Circulation. 1983 Oct;68(4):803–812. doi: 10.1161/01.cir.68.4.803. [DOI] [PubMed] [Google Scholar]
  126. Pfeffer M. A., Lamas G. A., Vaughan D. E., Parisi A. F., Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988 Jul 14;319(2):80–86. doi: 10.1056/NEJM198807143190204. [DOI] [PubMed] [Google Scholar]
  127. Pipili E., Manolopoulos V. G., Catravas J. D., Maragoudakis M. E. Angiotensin converting enzyme activity is present in the endothelium-denuded aorta. Br J Pharmacol. 1989 Oct;98(2):333–335. doi: 10.1111/j.1476-5381.1989.tb12599.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Piquilloud Y., Reinharz A., Roth M. Studies on the angiotensin converting enzyme with different substrates. Biochim Biophys Acta. 1970 Apr 22;206(1):136–142. doi: 10.1016/0005-2744(70)90090-2. [DOI] [PubMed] [Google Scholar]
  129. Polsky-Cynkin R., Fanburg B. L. Immunochemical comparison of angiotensin 1 converting enzymes from different rat organs. Int J Biochem. 1979;10(8):669–674. doi: 10.1016/0020-711x(79)90210-6. [DOI] [PubMed] [Google Scholar]
  130. Rademaker M., Shaw T. R., Williams B. C., Duncan F. M., Corrie J., Eglen A., Edwards C. R. Intravenous captopril treatment in patients with severe cardiac failure. Br Heart J. 1986 Feb;55(2):187–190. doi: 10.1136/hrt.55.2.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Raij L., Shultz P. J., Tolins J. P. Possible mechanism for the renoprotective effect of angiotensin converting enzyme inhibitors. J Hypertens Suppl. 1989 Sep;7(7):S33–S37. doi: 10.1097/00004872-198909007-00007. [DOI] [PubMed] [Google Scholar]
  132. Reams G. P., Souther M., Parisi M., Van Stone J. C., Bauer J. H. Arterial-venous determinations of the "immunoreactive" angiotensin peptides in human subjects. J Lab Clin Med. 1989 Jun;113(6):749–752. [PubMed] [Google Scholar]
  133. Remme W. J. Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations. Cardiovasc Drugs Ther. 1989 Jun;3(3):375–396. doi: 10.1007/BF01858109. [DOI] [PubMed] [Google Scholar]
  134. Romanelli G., Giustina A., Cimino A., Valentini U., Agabiti-Rosei E., Muiesan G., Giustina G. Short term effect of captopril on microalbuminuria induced by exercise in normotensive diabetics. BMJ. 1989 Feb 4;298(6669):284–288. doi: 10.1136/bmj.298.6669.284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Rosenthal J. H., Pfeifle B., Michailov M. L., Pschorr J., Jacob I. C., Dahlheim H. Investigations of components of the renin-angiotensin system in rat vascular tissue. Hypertension. 1984 May-Jun;6(3):383–390. doi: 10.1161/01.hyp.6.3.383. [DOI] [PubMed] [Google Scholar]
  136. Rosenthal J., von Lutterotti N., Thurnreiter M., Gomba S., Rothemund J., Reiter W., Kazda S., Garthoff B., Jacob I., Dahlheim H. Suppression of renin-angiotensin system in the heart of spontaneously hypertensive rats. J Hypertens Suppl. 1987 Jul;5(2):S23–S31. doi: 10.1097/00004872-198707002-00006. [DOI] [PubMed] [Google Scholar]
  137. Ryan J. W. Assay of peptidase and protease enzymes in vivo. Biochem Pharmacol. 1983 Jul 15;32(14):2127–2137. doi: 10.1016/0006-2952(83)90217-4. [DOI] [PubMed] [Google Scholar]
  138. Ryan J. W., Berryer P., Chung A. Assay of angiotensin converting enzyme in vivo. Adv Exp Med Biol. 1983;156(Pt B):805–812. [PubMed] [Google Scholar]
  139. Ryan J. W., Chung A., Ammons C., Carlton M. L. A simple radioassay for angiotensin-converting enzyme. Biochem J. 1977 Nov 1;167(2):501–504. doi: 10.1042/bj1670501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Ryan J. W., Chung A., Ryan U. S. Angiotensin-converting enzyme: I. New strategies for assay. Environ Health Perspect. 1980 Apr;35:165–170. doi: 10.1289/ehp.8035165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Ryan J. W., Ryan U. S. Metabolic functions of the pulmonary vascular endothelium. Adv Vet Sci Comp Med. 1982;26:79–98. [PubMed] [Google Scholar]
  142. Ryan U. S., Ryan J. W., Whitaker C., Chiu A. Localization of angiotensin converting enzyme (kininase II). II. Immunocytochemistry and immunofluorescence. Tissue Cell. 1976;8(1):125–145. doi: 10.1016/0040-8166(76)90025-2. [DOI] [PubMed] [Google Scholar]
  143. Said S. I. Metabolic functions of the pulmonary circulation. Circ Res. 1982 Mar;50(3):325–333. doi: 10.1161/01.res.50.3.325. [DOI] [PubMed] [Google Scholar]
  144. Saito K., Gutkind J. S., Saavedra J. M. Angiotensin II binding sites in the conduction system of rat hearts. Am J Physiol. 1987 Dec;253(6 Pt 2):H1618–H1622. doi: 10.1152/ajpheart.1987.253.6.H1618. [DOI] [PubMed] [Google Scholar]
  145. Sakaguchi K., Chai S. Y., Jackson B., Johnston C. I., Mendelsohn F. A. Differential angiotensin-converting enzyme inhibition in brain after oral administration of perindopril demonstrated by quantitative in vitro autoradiography. Neuroendocrinology. 1988 Sep;48(3):223–228. doi: 10.1159/000125015. [DOI] [PubMed] [Google Scholar]
  146. Sakaguchi K., Chai S. Y., Jackson B., Johnston C. I., Mendelsohn F. A. Inhibition of tissue angiotensin converting enzyme. Quantitation by autoradiography. Hypertension. 1988 Mar;11(3):230–238. doi: 10.1161/01.hyp.11.3.230. [DOI] [PubMed] [Google Scholar]
  147. Sakaguchi K., Jackson B., Chai S. Y., Mendelsohn F. A., Johnson C. I. Effects of perindopril on tissue angiotensin-converting enzyme activity demonstrated by quantitative in vitro autoradiography. J Cardiovasc Pharmacol. 1988 Dec;12(6):710–717. doi: 10.1097/00005344-198812000-00013. [DOI] [PubMed] [Google Scholar]
  148. Sakharov I. Y., Danilov S. M., Dukhanina E. A. Affinity chromatography and some properties of the angiotensin-converting enzyme from human heart. Biochim Biophys Acta. 1987 Jan 20;923(1):143–149. doi: 10.1016/0304-4165(87)90137-1. [DOI] [PubMed] [Google Scholar]
  149. Schalekamp M. A., Admiraal P. J., Derkx F. H. Estimation of regional metabolism and production of angiotensins in hypertensive subjects. Br J Clin Pharmacol. 1989;28 (Suppl 2):105S–113S. doi: 10.1111/j.1365-2125.1989.tb03586.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Seino M., Abe K., Nushiro N., Omata K., Yoshinaga K. Role of endogenous bradykinins in the acute depressor effect of angiotensin converting enzyme inhibitor captopril--assessed by a competitive antagonist of bradykinin. Clin Exp Hypertens A. 1989;11(1):35–43. doi: 10.3109/10641968909035289. [DOI] [PubMed] [Google Scholar]
  151. Semple P. F., Cumming A. M., Meredith P. A., Morton J. J. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man. Cardiovasc Drugs Ther. 1987;1(1):45–50. doi: 10.1007/BF02125832. [DOI] [PubMed] [Google Scholar]
  152. Semple P. F., Thorén P., Lever A. F. Vasovagal reactions to cardiovascular drugs: the first dose effect. J Hypertens. 1988 Aug;6(8):601–606. doi: 10.1097/00004872-198808000-00001. [DOI] [PubMed] [Google Scholar]
  153. Shapiro R., Riordan J. F. Inhibition of angiotensin converting enzyme: mechanism and substrate dependence. Biochemistry. 1984 Oct 23;23(22):5225–5233. doi: 10.1021/bi00317a021. [DOI] [PubMed] [Google Scholar]
  154. Siemienczuk D., Greenberg B., Broudy D. R. Effects of eating on cardiac performance in congestive heart failure. Chest. 1986 Aug;90(2):193–197. doi: 10.1378/chest.90.2.193. [DOI] [PubMed] [Google Scholar]
  155. Stanton R. C., Brenner B. M. Role of the kidney in congestive heart failure. Acta Med Scand Suppl. 1986;707:21–25. doi: 10.1111/j.0954-6820.1986.tb18110.x. [DOI] [PubMed] [Google Scholar]
  156. Strittmatter S. M., Snyder S. H. Characterization of angiotensin converting enzyme by [3H]captopril binding. Mol Pharmacol. 1986 Feb;29(2):142–148. [PubMed] [Google Scholar]
  157. Strittmatter S. M., Thiele E. A., Kapiloff M. S., Snyder S. H. A rat brain isozyme of angiotensin-converting enzyme. Unique specificity for amidated peptide substrates. J Biol Chem. 1985 Aug 15;260(17):9825–9832. [PubMed] [Google Scholar]
  158. Swales J. D., Heagerty A. M. Vascular renin-angiotensin system: the unanswered questions. J Hypertens Suppl. 1987 Jul;5(2):S1–S5. doi: 10.1097/00004872-198707002-00001. [DOI] [PubMed] [Google Scholar]
  159. Swartz S. L., Williams G. H., Hollenberg N. K., Moore T. J., Dluhy R. G. Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation. Hypertension. 1979 Mar-Apr;1(2):106–111. doi: 10.1161/01.hyp.1.2.106. [DOI] [PubMed] [Google Scholar]
  160. Sweet C. S., Arbegast P. T., Gaul S. L., Blaine E. H., Gross D. M. Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats. Eur J Pharmacol. 1981 Dec 3;76(2-3):167–176. doi: 10.1016/0014-2999(81)90498-2. [DOI] [PubMed] [Google Scholar]
  161. Swynghedauw B. Remodelling of the heart in response to chronic mechanical overload. Eur Heart J. 1989 Oct;10(10):935–943. doi: 10.1093/oxfordjournals.eurheartj.a059405. [DOI] [PubMed] [Google Scholar]
  162. Szelke M., Tree M., Leckie B. J., Jones D. M., Atrash B., Beattie S., Donovan B., Hallett A., Hughes M., Lever A. F. A transition-state analogue inhibitor of human renin (H.261): test in vitro and a comparison with captopril in the anaesthetized baboon. J Hypertens. 1985 Feb;3(1):13–18. doi: 10.1097/00004872-198502000-00003. [DOI] [PubMed] [Google Scholar]
  163. Taguma Y., Kitamoto Y., Futaki G., Ueda H., Monma H., Ishizaki M., Takahashi H., Sekino H., Sasaki Y. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985 Dec 26;313(26):1617–1620. doi: 10.1056/NEJM198512263132601. [DOI] [PubMed] [Google Scholar]
  164. Thollon C., Kreher P., Charlon V., Rossi A. Hypertrophy induced alteration of action potential and effects of the inhibition of angiotensin converting enzyme by perindopril in infarcted rat hearts. Cardiovasc Res. 1989 Mar;23(3):224–230. doi: 10.1093/cvr/23.3.224. [DOI] [PubMed] [Google Scholar]
  165. Till A. E., Gomez H. J., Hichens M., Bolognese J. A., McNabb W. R., Brooks B. A., Noormohamed F., Lant A. F. Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharm Drug Dispos. 1984 Jul-Sep;5(3):273–280. doi: 10.1002/bdd.2510050309. [DOI] [PubMed] [Google Scholar]
  166. Unger T., Moursi M., Ganten D., Hermann K., Lang R. E. Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498). J Cardiovasc Pharmacol. 1986 Mar-Apr;8(2):276–285. doi: 10.1097/00005344-198603000-00009. [DOI] [PubMed] [Google Scholar]
  167. Velletri P. A., Billingsley M. L., Lovenberg W. Thermal denaturation of rat pulmonary and testicular angiotensin-converting enzyme isozymes. Effects of chelators and CoCl2. Biochim Biophys Acta. 1985 Mar 29;839(1):71–82. doi: 10.1016/0304-4165(85)90183-7. [DOI] [PubMed] [Google Scholar]
  168. Vuk-Pavlović Z., Kreofsky T. J., Rohrbach M. S. Characteristics of monocyte angiotensin-converting enzyme (ACE) induction by dexamethasone. J Leukoc Biol. 1989 Jun;45(6):503–509. doi: 10.1002/jlb.45.6.503. [DOI] [PubMed] [Google Scholar]
  169. Waeber B., Brunner H. R., Brunner D. B., Curtet A. L., Turini G. A., Gavras H. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension. 1980 Mar-Apr;2(2):236–242. doi: 10.1161/01.hyp.2.2.236. [DOI] [PubMed] [Google Scholar]
  170. Welsch C., Grima M., Giesen E. M., Helwig J. J., Barthelmebs M., Coquard C., Imbs J. L. Assay of tissue angiotensin converting enzyme. J Cardiovasc Pharmacol. 1989;14 (Suppl 4):S26–S31. [PubMed] [Google Scholar]
  171. Xiang J. Z., Linz W., Becker H., Ganten D., Lang R. E., Schölkens B., Unger T. Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart. Eur J Pharmacol. 1985 Jul 17;113(2):215–223. doi: 10.1016/0014-2999(85)90738-1. [DOI] [PubMed] [Google Scholar]
  172. Yoshimura S., Imai K., Hayashi Y., Hashimoto K. Role of renin-angiotensin system in the pathogenesis of spontaneous myocardial fibrosis in Sprague-Dawley rats: effect of long-term administration of captopril. Tohoku J Exp Med. 1989 Mar;157(3):241–249. doi: 10.1620/tjem.157.241. [DOI] [PubMed] [Google Scholar]
  173. van Gilst W. H., de Graeff P. A., Wesseling H., de Langen C. D. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol. 1986 Jul-Aug;8(4):722–728. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES